Neuland Laboratories is currently trading at Rs. 920.90, up by 4.30 points or 0.47% from its previous closing of Rs. 916.60 on the BSE.
The scrip opened at Rs. 925.00 and has touched a high and low of Rs. 948.15 and Rs. 915.65 respectively. So far 3184 shares were traded on the counter.
The BSE group 'B ' stock of face value Rs. 10 has touched a 52 week high of Rs. 1041.00 on 13-Jul-2016 and a 52 week low of Rs. 462.00 on 30-Jul-2015.
Last one week high and low of the scrip stood at Rs. 982.00 and Rs. 909.65 respectively. The current market cap of the company is Rs. 824.37 crore.
The promoters holding in the company stood at 51.69%, while Institutions and Non-Institutions held 7.75% and 40.56% respectively.
Neuland Laboratories has entered into a Joint Development Agreement (JDA) with Phoenix Embassy Techno Zone for development of the land owned by the company at Nanakramguda near Hyderabad. The company would be entitled to receive approximately 23% share of the total saleable area of the project, which would be determined upon approval of the building plans by the appropriate authorities.
Neuland Laboratories manufactures active pharmaceutical ingredients for global pharmaceutical companies and provides end-to-end solutions for the pharmaceutical industry for chemistry-related services. It supplies to pharmaceutical companies across India, Europe and North America amongst others with a presence in over 85 countries. The company has two manufacturing facilities in Hyderabad, Telangana.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1808.20 |
| Dr. Reddys Lab | 1322.95 |
| Cipla | 1309.90 |
| Zydus Lifesciences | 891.65 |
| Lupin | 2303.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: